A
AdvanDx
Rapid diagnostics for critical infections. Improving antibiotic decisions and patient outcomes.
About AdvanDx
AdvanDx, a subsidiary of OpGen Inc., is a company specializing in molecular diagnostics. It develops and markets advanced molecular diagnostic products designed for the diagnosis and treatment of life-threatening infections. The company's flagship products, such as the QuickFISH platform, are FDA-approved and CE-marked for the rapid identification of pathogens directly from blood cultures. These tests can deliver results in as little as 20 minutes, a significant reduction from traditional methods that can take days.
The primary clients for AdvanDx are healthcare providers, including hospitals and clinical laboratories, that require rapid and accurate diagnostic information to guide patient treatment, particularly in cases of suspected sepsis or other serious infections. The business model is centered on the sale of these diagnostic kits and associated instrumentation. By providing faster diagnostics, AdvanDx helps to improve patient outcomes, reduce healthcare costs, and combat the growing problem of antimicrobial resistance by enabling more targeted antibiotic therapy.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2002
- Headquarters
- Woburn, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 56.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2015 | $0 | — | OpGen | — |
| DEBTDebt | Mar 2015 | $2.5M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for AdvanDx is 2.7K monthly website visits, up 170% over the last three months. AdvanDx's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
LD Pensions
SLS Venture
State of Wisconsin Investment Board
Stonehenge Capital
WARF Ventures
Mason Wells
Merck Global Health Innovation Fund
Series B and later1 investor entered at this stage
BioMérieux
Other known investors2 additional known investors
OpGen
University of Copenhagen
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AdvanDx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AdvanDx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.